NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $40.28 -1.29 (-3.10%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$40.07▼$41.9950-Day Range$27.71▼$41.8952-Week Range$13.72▼$42.67Volume770,101 shsAverage Volume797,622 shsMarket Capitalization$2.36 billionP/E Ratio16.51Dividend YieldN/APrice Target$42.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Protagonist Therapeutics alerts: Email Address Protagonist Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6.3% Upside$42.80 Price TargetShort InterestBearish5.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 14 Articles This WeekInsider TradingSelling Shares$1.83 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom $2.28 to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector828th out of 936 stocksPharmaceutical Preparations Industry387th out of 436 stocks 1.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Protagonist Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.56% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 59.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 3.0 News and Social Media Coverage News SentimentProtagonist Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Protagonist Therapeutics this week, compared to 3 articles on an average week.Search Interest7 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows2 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,831,650.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.28 to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 16.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 16.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.32.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Protagonist Therapeutics Stock (NASDAQ:PTGX)Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Read More PTGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTGX Stock News HeadlinesJune 28, 2024 | marketbeat.comNike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024Stocks that are trading heavily or have substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics riseJuly 25 at 7:39 AM | americanbankingnews.comBTIG Research Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $51.00July 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 25 at 1:46 AM | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Trading 3.2% Higher Following Analyst UpgradeJuly 23 at 5:15 AM | msn.comMost Overpowered Protagonist God Blessings In Manga And AnimeJuly 11, 2024 | investorplace.com3 Growth Stocks No One Is Watching (But They Should Be)June 27, 2024 | insidermonkey.comIs Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?June 5, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in June 2024July 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 28, 2024 | msn.comRichfield’s Protagonist Kitchen and Bar closes after two years in businessMay 28, 2024 | markets.businessinsider.comNurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical OfficerMay 24, 2024 | wsj.comProtagonist Therapeutics Inc.May 22, 2024 | money.usnews.comProtagonist Therapeutics IncMay 14, 2024 | finance.yahoo.comProtagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 CongressMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical TrialsMay 8, 2024 | markets.businessinsider.comProtagonist Therapeutics: Strong Buy Rating on Robust Financials and Promising PipelineMay 8, 2024 | investorplace.comPTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | chron.comProtagonist Therapeutics: Q1 Earnings SnapshotSee More Headlines Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$42.80 High Stock Price Target$51.00 Low Stock Price Target$32.00 Potential Upside/Downside+5.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$2.44 Trailing P/E Ratio16.70 Forward P/E Ratio17.87 P/E GrowthN/ANet Income$-78,960,000.00 Net MarginsN/A Pretax Margin52.53% Return on Equity43.42% Return on Assets39.59% Debt Debt-to-Equity RatioN/A Current Ratio15.72 Quick Ratio15.72 Sales & Book Value Annual Sales$60 million Price / Sales39.83 Cash FlowN/A Price / Cash FlowN/A Book Value$5.84 per share Price / Book6.98Miscellaneous Outstanding Shares58,650,000Free Float55,485,000Market Cap$2.39 billion OptionableOptionable Beta2.13 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 67)CEO, President, Secretary & Director Comp: $883.46kDr. Suneel K. Gupta Ph.D. (Age 65)Chief Development Officer Comp: $640.89kDr. Mark Smythe Ph.D. (Age 59)Founder & VP Technology Mr. Asif Ali (Age 50)Executive VP & Chief Financial Officer Mr. Mohammad Masjedizadeh Ph.D.Executive VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 53)Executive VP & General Counsel Ms. Carena SpiveyHead of HR & Senior VP of Human ResourcesDr. Ashok Bhandari Ph.D. (Age 60)Executive VP & Chief Drug Discovery and Preclinical Development Officer Mr. Carter J. King (Age 53)Executive Vice President of Business Development Ms. Abha BommireddiExecutive Vice President of Portfolio & Program ManagementMore ExecutivesKey CompetitorsFive Prime TherapeuticsNASDAQ:FPRXCalliditas Therapeutics AB (publ)NASDAQ:CALTPhibro Animal HealthNASDAQ:PAHCEsperion TherapeuticsNASDAQ:ESPRCara TherapeuticsNASDAQ:CARAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 17,065 shares on 7/26/2024Ownership: 0.348%William D WaddillSold 8,000 sharesTotal: $320,000.00 ($40.00/share)Hennion & Walsh Asset Management Inc.Bought 2,985 shares on 7/20/2024Ownership: 0.065%SG Americas Securities LLCBought 10,951 shares on 7/12/2024Ownership: 0.019%Dinesh V Ph D PatelSold 35,000 sharesTotal: $1.23 M ($35.19/share)View All Insider TransactionsView All Institutional Transactions PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $22.93 at the beginning of the year. Since then, PTGX shares have increased by 75.7% and is now trading at $40.28. View the best growth stocks for 2024 here. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its quarterly earnings data on Tuesday, May, 7th. The company reported $3.26 earnings per share for the quarter, topping analysts' consensus estimates of $2.51 by $0.75. The firm had revenue of $254.95 million for the quarter, compared to the consensus estimate of $300 million. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Top institutional shareholders of Protagonist Therapeutics include Bank of New York Mellon Corp (0.35%), Hennion & Walsh Asset Management Inc. (0.06%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Asif Ali and David Y Liu. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP) and Verastem (VSTM). This page (NASDAQ:PTGX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
